

**Adult CIRB - Late Phase Emphasis Meeting Agenda**

**May 2, 2024**

---

**I Amendment**

**S2000**, A Randomized Phase II Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Symptomatic Brain Metastases (Version Date 03/19/24)

---

**II Continuing Review**

**S2104**, Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors (Version Date 08/18/23)

---

**III Continuing Review**

**S2212**, Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study (Version Date 06/20/23)

---

**IV Continuing Review**

**A031801**, A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RadiCaL) (Version Date 02/15/22)

---

**V Continuing Review**

**A052101**, A Randomized Phase 3 Trial of Continuous vs Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma (INTERCON) (Version Date 11/21/23)

---

## **VI Continuing Review**

**EA1183**, FDG PET to Assess Therapeutic Response in Patients with Bone-dominant Metastatic Breast Cancer, FEATURE (Version Date 10/21/22)

---

## **VII Continuing Review**

**EA2183**, A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA) (Version Date 03/28/24)

---

## **VIII Continuing Review**

**NRG-BR004**, A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer (Version Date 08/15/22)

---

## **IX Continuing Review**

**NRG-GI008**, Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA) (Version Date 09/25/23)

---